Serán Bioscience breaks ground on additional cGMP manufacturing capacity at its Bend site.
Due to exceptionally high demand for cGMP manufacturing of complex medicines, Seran is doubling its existing clinical manufacturing facility from 7 to 14 suites. The new state-of-the-art facility is designed to be highly configurable and flexible to meet our clients' unique needs. All cleanrooms will have ISO 8 classification to efficiently support a variety of enabling manufacturing operations. With this investment, Serán will be able to significantly increase its production capacity to manufacture complex formulations and advance novel medicines into early and late-stage clinical studies.
Serán employs a range of novel technologies and pharmaceutical manufacturing operations to overcome drug development challenges for both small and large molecules, including complex granulations, spray dried dispersions, hot melt extrudates, IR and MR tablet technologies, multiparticulates, and engineered particles for inhalation. The facility expansion leverages Serán’s expertise and commitment to supporting its large and small pharmaceutical customers from early to late-stage clinical manufacturing.
Serán has over 190 team members and 10 facilities with ~ 90,000 square feet in Bend, OR. Serán’s leadership team has been at the forefront of enabling pharmaceutical technologies for decades. The state-of-the-art manufacturing facilities in Bend are equipped with the latest technologies that empower pharmaceutical dosage-form solutions that are not just effective, but transformative. This new facility embodies Serán’s commitment to innovation.
The cGMP facility capacity expansion is expected to be complete in the second quarter of 2024.
For more information, contact us at firstname.lastname@example.org.